|Bid||34.66 x 800|
|Ask||34.67 x 1300|
|Day's Range||34.56 - 36.09|
|52 Week Range||30.33 - 47.82|
|Beta (3Y Monthly)||1.30|
|PE Ratio (TTM)||39.97|
|Earnings Date||Nov 5, 2018 - Nov 9, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||44.63|
On CNBC's "Mad Money Lightning Round" , Jim Cramer said he would stay away from Sociedad Quimica y Minera de Chile (NYSE: SQM ). He doesn't see any edge that could make him money in the stock. ...
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Theravance Biopharma Inc and partner Mylan NV on Friday won U.S. regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems. The treatment, Yupelri https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210598s000lbl.pdf, is a once-daily inhalable solution to be used by patients of chronic obstructive pulmonary disease (COPD), a lung disease characterized by wheezing or chronic cough. Yupelri belongs to a class of drugs called long-acting muscarinic antagonists (LAMA), with the existing treatment options primarily being hand-held devices such as Boehringer Ingelheim's Spiriva.
DUBLIN, Ireland, HERTFORDSHIRE, England and PITTSBURGH, Nov. 9, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (MYL) ("Mylan") today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for YUPELRITM (revefenacin) inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI, a long-acting muscarinic antagonist (LAMA), is the first and only once-daily, nebulized bronchodilator approved for the treatment of COPD in the US. The companies expect YUPELRI to be available to COPD patients in the US before the end of the year.
Concerns over rising interest rates and expected further rate increases have hit several stocks hard since the end of the third quarter. The NASDAQ and Russell 2000 indices are already in correction territory. More importantly, the Russell 2000 ETF (IWM) underperformed the larger S&P 500 ETF (SPY) by about 4 percentage points in October. Hedge […]
On June 4, the FDA issued a press release announcing regulatory approval for a biosimilar version of Amgen’s (AMGN) Neulasta and Mylan’s (MYL) Fulphilia. On September 20, the European Medicines Agency issued a press release announcing a positive opinion from the Committee for Medicinal Products for Human Use for Fulphila. According to Mylan’s investor presentation, Fulphila is targeting a global market opportunity worth more than $5.0 billion.
In the third quarter, Mylan (MYL) reported net sales of $1.04 billion from the European market, which is a flat performance on a YoY (year-over-year) basis. According to Mylan’s third-quarter earnings conference call, the company has witnessed strong demand for branded generics and over-the-counter products in the European market. According to Mylan’s investor presentation, the company has a presence in 35 countries and offers more than 1,500 products in the European market. Mylan is already a leader in terms of value and volume in France and Italy’s generic drug markets.
Whenever a stock shoots higher, value investors justifiably hesitate on trading it. The stock priced in the good news already, leaving few extra gains ahead. So when Mylan N.V. (NASDAQ: MYL) rose by over 15% on the week, the best thing investors may do before buying Mylan stock is to look at the quarterly earnings result in detail.
In the third quarter, Mylan (MYL) reported net sales of $1.01 billion from the North American market, which is a 14% decline on a YoY (year-over-year) basis. According to Mylan’s third-quarter earnings conference call, the revenue drop was due to reduced sales volumes of existing products, including Epipen. According to Mylan’s third-quarter earnings conference call, the lower sales volumes in the third quarter were due to the timing of customers’ purchases and the restructuring and remediation program that was started at the Morgantown manufacturing facility in the second quarter.
According to Mylan’s (MYL) third-quarter earnings conference call, the company expects to witness an adjusted EPS of $4.55–$4.90 in 2018. Wall Street analysts expect Mylan to report an adjusted EPS of $4.70 in 2018, which will be a rise of 2.99% YoY. Wall Street analysts also expect Mylan to report an adjusted EPS of $5.59 in 2020, which will be a rise of 8.47% YoY.
According to Mylan’s (MYL) third-quarter earnings conference call, the company expects to witness revenues of $11.25 billion–$12.25 billion in 2018. Wall Street analysts expect Mylan to report revenues of $11.50 billion in 2018, which will be a decline of 3.44% YoY. Wall Street analysts also expect Mylan to report revenues of $12.46 billion in 2020, which will be a rise of 3.72% YoY.
On November 6, Mylan (MYL) closed at $36.43, which was 16.13% higher than its previous closing price. The stock was trading 12.33% higher than its closing price of $32.43 on November 1. Based on Mylan’s closing price on November 6, the company witnessed returns of 16.35% in the last week, 3.17% in the last month, and -7.14% in the last quarter.
Generic drugmaker Mylan’s last quarterly report was marked by poor financial results and other discouraging developments, leading many investors to worry that the sky was falling, according to Leerink analyst Ami Fadia. Mylan’s (MYL)third-quarter results, which included a profit beat, sent the company’s shares up 16% on Tuesday and spurred a turnaround in Wall Street sentiment. “Bigger picture, we see recent weakness in MYL as overdone,” said J.P. Morgan analyst Chris Schott.
Election day was unsurprisingly tame, with most investors willing to wait at least one more day to make trades so they can make some decisions in light of who is (or isn’t) in office. Click to Enlarge • The weekly chart isn’t tough to interpret.
U.S. stock futures held onto gains on Tuesday after media projections showed the Democrats winning control of the House of Representatives in U.S. midterm congressional elections. With President Donald Trump's Republican party holding onto their majority in the Senate, according to CNN, NBC and ABC News, the results were in line with expectations on Wall Street that Washington was set for gridlock.
Though many believe gridlock in Washington is good for Wall Street, stocks usually rally after the midterms no matter what the results are.
Wall Street's major indexes closed higher on Tuesday as voters headed to the polls in U.S. midterm congressional elections and investors hoped the result would provide some relief for stocks after prolonged uncertainty. Some stocks such as CVS Health Corp and Mylan NV were boosted by strong earnings, but despite a late afternoon spike in buying, trading volume was relatively thin as many investors held back on making big bets in case of a surprise election outcome. Wall Street had been expecting that President Donald Trump's Republican party would lose control of the House of Representatives, while retaining the Senate.
Can they hold above this mark and get back above channel support (blue line)? If it can, the 21-day near $23 and channel resistance near $24 are in the cards. A top and bottom-line beat propelled shares of CVS Health (NYSE:CVS) higher by 5% on Tuesday.
Investing.com - A pulsating rally in shares of Mylan and CVS Health Tuesday offset weakness in Eli Lilly, keeping the broader health care sector well above the flatline.